Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × selinexor × Clear all

Phase

Phase 1 24 Phase 2 7 Phase 1/2 6 Phase 3 2 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Fluorouracil 21 Cisplatin 20 Oxaliplatin 15 Gemcitabine 15 Radiotherapy 14 Docetaxel 14 Paclitaxel 13 Capecitabine 13 Carboplatin 12 Bevacizumab 12 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Drug Therapy 10 Cytarabine 9 Magnetic Resonance Spectroscopy 7 Dexamethasone 7 Saline Solution 6 Rituximab 6 Nivolumab 6 Methotrexate 6 Letrozole 6 Exercise 6 Etoposide 6 Electroporation 6 pembrolizumab 5 Melphalan 5 Lidocaine 5 Filgrastim 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡